MADRID, February 24, 2011 /PRNewswire/ -- Zeltia Group's net revenues totalled 153.5 million euro in 2010, 24.4 percent more than in 2009 (123.4 million euro). This performance is primarily attributable to a 70 percent increase in Yondelis(R) sales.

Net sales in the Biopharmaceutical business amounted to 79.4 million euro in 2010 (51.1 million euro in 2009), of which 72.1 million correspond to Yondelis(R) (43.8 million euro in 2009).

The Biopharmaceutical segment accounted for 52 percent of total Group revenues in 2010, exceeding for the first time the contribution from the Consumer Chemicals business (73.2 million euro in 2010, compared with 71.1 million euro in 2009).

EBITDA improved by 74 percent in 2010 to -3.9 million euro (-15.3 million euro in 2009).

Net income attributable to the parent company rose 71 percent with respect to 2009.